Table 2 Association between the XRCC1 Arg194Trp and Arg399Gln polymorphisms and median survival time, median time to progression, and median progression-free survival of platinum-based chemotherapy in advanced lung cancer patients.

From: Predictive assessment in pharmacogenetics of XRCC1 gene on clinical outcomes of advanced lung cancer patients treated with platinum-based chemotherapy

Study

Year

 

Arg194Trp(95%-CI)

Trp/Trp+Trp/Arg

ArgArg

Arg399Gln(95%-CI)

Gln/Gln+Gln/Arg

ArgArg

TrpTrp

TrpArg

GlnGln

GlnArg

Cheng et al.,

2011

MST

11.10

15.20

Giachino et al.,

2007

MST

18.67

12.74

12.97

 

HR

0.60

1.17

1(Reference)

(0.35–1.03)

(0.85–1.59)

de las Penas R. et al.,

2006

MST

10.56

13.95

10.86

(5.03–16.09)

(10.92–16.97)

(7.40–14.31)

 

HR

1.59

1(Reference)

1.51

(0.81–3.10)

(1.03–2.40)

Gurubhagavatula et al.,

2004

MST

7.70

11.40

17.30

 

HR

3.17

1.22

1(Reference)

(1.48–6.77)

(0.76–1.94)

Kalikaki et al.,

2009

MST

7.10

11.30

14.80

(0.30–13.90)

(8.90–13.80)

(9.10–20.50)

 

HR

4.58

1.43

1(Reference)

(1.92–10.92)

(0.85–2.40)

Liu et al.,

2008

MST

8.00

16.00

24.00

(5.90–10.10)

(13.90–18.10

(16.50–31.50)

 

HR

6.24

1.44

1(Reference)

(1.86–20.91)

(0.66–3.12)

Han et al.,

2011

MST

 

HR

1(Reference)

1.35

(0.90–2.00)

Yao et al.,

2009

MST

15.00

21.00

29.00

(11.90–21.10)

(11.50–30.90)

(7.00–39.00)

 

HR

    

1(Reference)

0.83

0.58

(0.49–1.41)

(0.17–2.04)

Yuan et al.,

2010

MST

15.00

17.00

17.00

16.00

14.00

16.00

16.00

17.00

(9.05–20.50)

(14.40–19.90)

(14.60–19.40)

(10.90–21.10)

(5.70–22.30)

(11.40–20.60)

(12.10–19.9)

(13.80–20.20)

 

HR

1.23

0.94

1.00

1(Reference)

1.13

1.25

1.23

1(Reference)

(0.73–2.10)

(0.66–1.34)

(0.71–1.39)

(0.63–2.03)

(0.88–1.79)

(0.88–1.71)

Wang et al. ,

2006

MST

13.00

11.00

10.00

14.00

Joerger et al.,

2012

MST

6.00

10.40

10.80

(2.30–9.30)

(9.40–13.70)

(7.30–15.90)

 

HR

1(Reference)

0.62

0.56

(0.34–1.11)

(0.30–1.01)

Zhou et al.,

2014

MST

  

10.00

12.00

Yang et al.,

2013

MST

  

14.00

10.00

Ke et al.,

2012

MST

 

HR

0.45

1.23

1(Reference)

0.42

0.76

1(Reference)

(0.23–0.87)

(0.81–1.89)

(0.21–0.82)

(0.53–1.07)

Lee et al.,

2013

MST

9.80

13.00

14.40

(2.60–17.00)

(11.10–15.00)

(12.70–16.10)

 

HR

1.47

1.13

1(Reference)

(0.91–2.37)

(0.90–1.42)

Liao et al.,

2012

MST

22.00

(10.00–34.00)

 

HR

0.25

0.26

1(Reference)

(0.03–1.88)

(0.11–0.64)

Liao et al.,

2012

MST

45.00

29.00

(36.00–54.00)

(20.00–38.00)

 

HR

0.47

1(Reference)

(0.25–0.92)

Zhao et al.,

2013

MST

8.50a

32.00

14.60a

5.70a

36.00

32.00

 

HR

1.13

0.84

0.88

1(Reference)

1.32

0.83

0.89

1(Reference)

(0.30–4.17)

(0.45–1.58)

(0.48–1.61)

(0.43–4.00)

(0.44–1.57)

(0.49–1.62)

Hong et al.,

2011

MST

15.00

19.00

(8.55–21.45)

(15.00–23.00)

 

HR

1.27

1(Reference)

(0.93–1.75)

Peng et al.,

2014

MST

16.00

12.00

12.00

17.00

(0.00–33.53)

(10.03–13.97)

(10.03–13.97)

(14.69–19.31)

 

HR

1(Reference)

1.69

(1.19–2.40)

Zhang et al.,

2014

MST

26.60

25.30

25.90

23.40

27.50

23.70

25.60

22.30

(14.90–28.80)

(14.40–29.40)

(13.80–29.10)

(14.20–28.50)

(15.80–32.30)

(14.30–27.40)

(15.20–28.20)

(13.50–27.20)

 

HR

0.83

0.79

0.81

1(Reference)

0.48

0.74

0.55

1(Reference)

(0.51–1.62)

(0.55–1.67)

(0.56–1.66)

(0.25–0.86)

(0.48–1.53)

(0.23–0.94)

Jin

2014

MST

 

HR

0.82

0.91

1(Reference)

0.51

0.87

1(Reference)

(0.47–1.39)

(0.61–1.33)

(0.26–0.98)

(0.60–1.24)

Kalikaki et al.,

2015

MST

10.80

10.80

(7.30–14.30)

(4.60–17.90)

 

HR

1.01

1(Reference)

(0.64–1.50)

Liu et al.,

2008

Median TTP

4.10

6.00

11.00

(2.30–5.90)

(3.10–8.90)

(6.40–15.60)

 

HR

1.91

1.00

1(Reference)

(0.62–5.83)

(0.50–2.04)

Zhou et al.,

2011

Median TTP

6.00

8.50

(5.50–6.50)

(7.86–9.14)

Zhou et al.,

2011

Median TTP

6.50

7.00

(5.90–7.10)

(6.04–7.96)

Han et al.,

2011

Median TTP

5.00

9.50

Yuan et al.,

2010

Median PFS

6.80

7.00

6.80

6.90

6.90

6.90

6.90

6.80

(4.30–9.30)

(6.00–8.00)

(5.60–8.00)

(5.60–8.30)

(2.50–11.30)

(6.00–7.80)

(6.00–7.80)

(5.60–8.00)

 

HR

1.31

1.10

1.14

1(Reference)

0.69

1.08

0.98

1(Reference)

(0.77–2.23)

(0.78–1.57)

(0.82–1.59)

(0.38–1.25)

(0.76–1.53)

(0.71–1.35)

Joerger et al.,

2012

Median PFS

4.80

6.30

5.20

(1.40–7.30)

(5.30–8.10)

(3.50–7.60)

 

HR

1(Reference)

0.91

1.03

(0.53–1.58)

(0.59–1.82)

Liao et al.,

2012

Median PFS

5.10

5.10

5.80

(3.10–7.20)

(3.30–7.00)

(4.20–7.40)

Zhao et al.,

2013

Median PFS

6.70a

9.00

11.50

8.00

12.00

10.00

 

HR

0.56

1.12

1(Reference)

1.33

0.73

1(Reference)

(0.16–1.95)

(0.70–1.80)

(0.56–3.19)

(0.45–1.19)

Deng et al.,

2013

Median PFS

6.07

6.23

 

HR

  

0.81

1(Reference)

(0.51–1.27)

Peng et al.,

2014

Median PFS

2.00

6.00

6.00

7.00

(1.03–2.97)

(4.21–7.80)

(4.33–7.67)

(5.69–8.31)

Zhang et al.,

2014

Median PFS

9.40

8.70

8.80

8.60

10.90

8.50

10.40

7.80

(4.20–16.40)

(3.80–15.10)

(4.30–16.30)

(3.40–14.20)

(5.40–18.60)

(3.20–14.20)

(5.10–18.30)

(3.20–13.60)

 

HR

0.83

0.89

0.85

1(Reference)

0.51

0.79

0.61

1(Reference)

(0.42–1.43)

(0.54–1.60)

(0.57–1.59)

(0.23–0.96)

(0.52–1.58)

(0.31–1.22)

Kalikaki et al.,

2015

Median PFS

4.40

5.60

(3.00–6.10)

(3.20–8.10)

 

HR

   

0.83

1(Reference)

(0.55-1.26)

  1. Note: HR: hazard ratio; MST, median survival time (months); TTP, time to progression (months); PFS, progression-free survival (months).
  2. aThe mean survival time is shown in the reference.